| 汤洁,彭佳惠,张梦媛,等.新型口服抗凝药物拮抗剂的研究进展[J].中国临床保健杂志,2019,22(1):130-133. |
| 新型口服抗凝药物拮抗剂的研究进展 |
| Research progress of specific antagonists for new oral anticoagulants |
| 投稿时间：2018-05-10 |
| DOI：10.3969/J.issn.1672-6790.2019.01.034 |
| 中文关键词: 抗凝药,口服 心房颤动 拮抗剂 |
| 英文关键词: Anticoagulants,Oral Atrial fibrillation Antagonists 〖FL |
| 基金项目:安徽省公益性联动项目(1604f0804009) |
|
| 摘要点击次数: 6335 |
| 全文下载次数: 6353 |
| 中文摘要: |
| 心房颤动患者大多需要口服抗凝药物,传统抗凝药物华法林应用临床已逾60年,尽管其作用明确,但存在各种局限性。近年来新型口服抗凝药(new oral anticoagulant,NOAC)的问世弥补了华法林的不足,因具有更好的风险/获益比,成为心房颤动患者的新选择。虽然NOACs有着众多优点,然而缺少特异性的拮抗剂仍限制了其临床应用。不过,目前NOACs拮抗剂的研究已经取得了突破性的进展,2015年10月美国FDA通过加速审批程序批准idarucizumab作为达比加群酯的唯一拮抗剂。2018年5月Andexxa获FDA批准作为Xa抑制剂的首个及唯一特异性拮抗药物,另外,目前处于研究阶段的Ciraparantag也有望成为NOACs的特异性拮抗剂。该文将对上述药物的研究进展作简要的综述。 |
| 英文摘要: |
| Anticoagulation drugs are used widely for the prevention of thromboembolism in patients with atrial fibrillation.Warfarin,a traditional anticoagulant drug,its effect is exact,but there are many limitations.In recent years,the advent of new oral anticoagulants (NOAC) made up for the inadequacy of warfarin,which become a new choice for patients with atrial fibrillation due to better risk/benefit ratio.Although NOACs have many virtues,the lack of specific antagonists limits its clinical application.However,a breakthrough has been made in research of antagonists for NOACs.In October 2015,idarucizumab has been approved as the only reversal agents for dabigatran by FDA.In addition,both Andexanetalfa and Ciraparantag are expected to become specificity antagonists for NOACs,while they are still in research stage at present.In this review,the research progress of the above drugs are briefly summarized. |
|
查看全文
|
| 关闭 |
|
|
|